Cardiology content commonly referenced by physicians includes a combination of clinical guidelines, randomized trial data, pharmacologic therapies, and validated risk assessment tools. The following 10-item framework reflects widely used sources that inform cardiovascular care.

1. American College of Cardiology (ACC)/American Heart Association (AHA) Dyslipidemia Guideline (2026) — The 2026 multisociety ACC/AHA guideline replaces the 2018 cholesterol guideline and provides evidence-based recommendations for the evaluation, management, and monitoring of dyslipidemias, including elevated cholesterol, triglycerides, and lipoprotein(a), based on a systematic review of clinical evidence.

2. European Society of Cardiology (ESC) Dyslipidemia Guideline Update (2025) — The 2025 focused update revises recommendations for dyslipidemia treatment using evidence published since 2019, including combination lipid-lowering therapy and updated risk modifiers such as lipoprotein(a), with updates limited to findings supporting changes in key recommendation classes.

3. 2022 AHA/ACC/Heart Failure Society of America (HFSA) Heart Failure Guideline — The 2022 AHA, ACC, and HFSA guideline updates prior recommendations by incorporating recent evidence to provide patient-centered guidance for the prevention, diagnosis, and management of heart failure based on a comprehensive review of clinical studies.

4. 2019 ESC/European Atherosclerosis Society (EAS) Dyslipidemia Guidelines— The 2019 ESC and EAS guideline provides recommendations for lipid evaluation and management, including cardiovascular risk stratification and treatment targets for low-density lipoprotein cholesterol.

5. FOURIER Trial (2017) — In a randomized, placebo-controlled trial of patients with atherosclerotic cardiovascular disease receiving statin therapy, evolocumab significantly reduced low-density lipoprotein cholesterol levels and was associated with a lower risk of major cardiovascular events.

6. PARADIGM-HF Trial (2014) — In a randomized trial of patients with heart failure with reduced ejection fraction, the angiotensin receptor–neprilysin inhibitor LCZ696 reduced the risks of cardiovascular death and hospitalization for heart failure compared with enalapril.

7. EMPA-REG OUTCOME Trial (2015) — In a randomized trial of patients with type 2 diabetes at high cardiovascular risk, empagliflozin added to standard care was associated with a lower risk of major cardiovascular events and death compared with placebo.

8. DAPA-HF Trial (2019) — In a randomized trial of patients with heart failure with reduced ejection fraction, dapagliflozin added to standard therapy was associated with a reduced risk of worsening heart failure or cardiovascular death compared with placebo, regardless of diabetes status.

9. PREVENT Risk Equations (AHA Tool) — The PREVENT risk equations are clinical tools developed by the AHA to estimate 10- and 30-year risk of atherosclerotic cardiovascular disease, heart failure, and total cardiovascular disease in adults without established cardiovascular disease using multiple patient-specific factors.

10. CHA₂DS₂-VASc Score (ESC Reference) — An updated clinical risk assessment tool that removes the gender criterion to estimate stroke risk in patients with atrial fibrillation.

Sources: The Journal of the American College of Cardiology, European Heart Journal, Circulation, The New England Journal of Medicine, American College of Cardiology, American Heart Association, European Society of Cardiology